M.E.G. Naranjo

High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

María Apellániz-Ruiz, Lucía Inglada‐Pérez, M.E.G. Naranjo et al. · The Pharmacogenomics Journal · 2014 · 66 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances

Eva Peñas‐Lledó, Sébastien Guillaume, M.E.G. Naranjo et al. · The Pharmacogenomics Journal · 2014 · 30 citations

Medicine, Pharmacokinetics, Pharmacology +11

<i>CYP2D6</i>Gene Polymorphisms and Predicted Phenotypes in Eight Indigenous Groups from Northwestern Mexico

Blanca Patricia Lazalde-Ramos, Carlos Galavíz-Hernández, Idalia Garza‐Veloz et al. · Pharmacogenomics · 2014 · 30 citations

Medicine, Genetics, Molecular Genetics +15

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies

M.E.G. Naranjo, A. Delgado, J. Cobaleda et al. · The Pharmacogenomics Journal · 2016 · 27 citations · Full text

Medicine, Biochemistry, Pharmacology +13

Lessons from Cuba for Global Precision Medicine: <i>CYP2D6</i> Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism

Pedro Dorado, Idilio González, M.E.G. Naranjo et al. · OMICS A Journal of Integrative Biology · 2017 · 25 citations

Medicine, Pharmacokinetics, Pharmacology +17